Morgan Stanley’s Prime Medicine PRME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.23M Sell
639,457
-530,441
-45% -$2.02M ﹤0.01% 4700
2025
Q4
$4.06M Buy
1,169,898
+438,894
+60% +$1.95M ﹤0.01% 4340
2025
Q3
$4.05M Buy
731,004
+143,328
+24% +$582K ﹤0.01% 4318
2025
Q2
$1.45M Buy
587,676
+232,500
+65% +$358K ﹤0.01% 4906
2025
Q1
$707K Buy
355,176
+43,900
+14% +$112K ﹤0.01% 5173
2024
Q4
$909K Buy
311,276
+10,885
+4% +$38.2K ﹤0.01% 5142
2024
Q3
$1.16M Buy
300,391
+116,426
+63% +$539K ﹤0.01% 4963
2024
Q2
$946K Sell
183,965
-14,501
-7% -$87.9K ﹤0.01% 4993
2024
Q1
$1.39M Sell
198,466
-225,002
-53% -$1.71M ﹤0.01% 4788
2023
Q4
$3.75M Buy
423,468
+380,677
+890% +$2.93M ﹤0.01% 4547
2023
Q3
$408K Sell
42,791
-15,138
-26% -$197K ﹤0.01% 5256
2023
Q2
$849K Buy
57,929
+24,544
+74% +$343K ﹤0.01% 4928
2023
Q1
$411K Buy
33,385
+12,996
+64% +$212K ﹤0.01% 5366
2022
Q4
$379K Buy
+20,389
New +$368K ﹤0.01% 5378

Other funds holding PRME